Molecular imaging with copper-64 in the drug discovery and development arena.

No Thumbnail Available
Date
2007-05-01
Journal Title
Journal ISSN
Volume Title
Publisher
Informa Healthcare
Abstract
The contribution of positron emission tomography (PET) to the drug discovery and development (D3) pipeline has been inhibited by the short half-lifes of PET radioisotopes, 11C and 18F, poor availability and the high cost of infrastructure. Copper-64 (64Cu) has a 12.7 h half-life, simple yet flexible radiochemistry and imaging characteristics that make it ideal for a wider application across the D3 arena. Recent scientific breakthroughs in the production of 64Cu show that it's, commercial production can be made more widely available. More importantly, for pharmaceutical research and development programmes wishing to incorporate the high sensitivity and spatial resolution of PET, but no desire to implement and maintain expensive radiochemistry infrastructure, 64Cu is an exciting option. © 2007, Informa Healthcare
Description
Keywords
Drugs, Positron computed tomography, Copper 64, Clinical trials, Images, Radiochemistry
Citation
Smith, S. V. (2007). Molecular imaging with copper-64 in the drug discovery and development arena. Expert Opinion on Drug Discovery, 2(5), 659-672. doi:10.1517/17460441.2.5.659
Collections